Spago Nanomedical AB (FRA:7UX) Current Deferred Taxes Liabilities: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7UX Spago Nanomedical AB FRA:7UX
32 GF Score
Price €0.01
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB Current Deferred Taxes Liabilities?

Spago Nanomedical AB FRA:7UX 32 Current Deferred Taxes Liabilities is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:7UX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Spago Nanomedical AB's current deferred tax liabilities for the quarter that ended in Jun. 2026 was €0.00 Mil.

Spago Nanomedical AB Current Deferred Taxes Liabilities Related Terms


Spago Nanomedical AB Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Spago Nanomedical AB's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB Current Deferred Taxes Liabilities Chart

Spago Nanomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spago Nanomedical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7UX
32GF Score
Spago Nanomedical AB FRA:7UX
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of €0.00 Mil mean?
Spago Nanomedical AB (FRA:7UX) has a Current Deferred Taxes Liabilities of €0.00 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Current Deferred Taxes Liabilities too high?
Spago Nanomedical AB's current Current Deferred Taxes Liabilities is €0.00 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Current Deferred Taxes Liabilities compare to VRTX and REGN?
Spago Nanomedical AB's Current Deferred Taxes Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Current Deferred Taxes Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current Current Deferred Taxes Liabilities of €0.00 Mil. The current Current Deferred Taxes Liabilities is €0.00 Mil. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current Current Deferred Taxes Liabilities is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spago Nanomedical AB Business Description

Other Exchanges SPAGO:Sweden
Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score

Get the complete analysis for FRA:7UX

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price